Overview Financials News + Filings Key Docs Charts Ownership Insiders
|
|
Sagent Pharmaceuticals, Inc. (SGNT)
|
Add to portfolio |
|
|
|
| Price: |
$11.45
| | Metrics |
| OS: |
32.9
|
M
| |
-10
|
% ROE
|
| Market cap: |
$377
|
M
| |
23
|
% ROIC
|
|
Net cash:
|
$29.7
|
M
| |
$0.90
|
per share
|
|
EV:
|
$347
|
M
| | | |
| | | | | |
| TTM Valuation | | | |
|
EBITDA
|
$18.1
|
M
| |
19.2
|
x EV/EBITDA
|
|
EBIT
|
$6.1
|
M
| |
56.7
|
x EV/EBIT
|
| EPS |
($0.77)
| |
|
|
|
|
| |
|
|
|
Recent News + Filings (All items)
|
Revenue Mix by Segment
|
Financial Summary (All financials)
| In millions, except per share items | Dec-31-15 | Dec-31-14 | Dec-31-13 | Dec-31-12 | Dec-31-11 | Dec-31-10 | Dec-31-09 | Dec-31-08 |
| Revenues | 318.3 | 289.0 | 244.8 | 183.6 | 152.4 | 74.1 | 29.2 | 12.0 |
| Revenue growth | 10.1% | 18.1% | 33.3% | 20.5% | 105.8% | 153.4% | 143.4% | |
| Cost of goods sold | 230.6 | 202.8 | 167.2 | 152.5 | 133.6 | 65.0 | 28.8 | 11.9 |
| Gross profit | 87.7 | 86.2 | 77.5 | 31.1 | 18.8 | 9.0 | 0.4 | 0.1 |
| Gross margin | 27.6% | 29.8% | 31.7% | 16.9% | 12.3% | 12.2% | 1.5% | 0.6% |
| Selling, general and administrative | 49.9 | 43.2 | 36.2 | 30.1 | 25.1 | 18.9 | 16.7 | 15.0 |
| Research and development | 29.1 | 26.8 | 20.3 | 17.1 | 12.8 | 11.2 | 12.4 | 14.9 |
| EBITA | 11.2 | 20.1 | 31.4 | -14.8 | -21.7 | -22.6 | -26.2 | -30.3 |
| EBITA margin | 3.5% | 7.0% | 12.8% | -8.1% | -14.2% | -30.5% | -89.6% | -252.5% |
| Amortization of intangibles | | | | | | | 4.0 | 1.8 |
| EBIT | 11.2 | 20.1 | 31.4 | -14.8 | -21.7 | -22.6 | -30.1 | -32.1 |
| EBIT margin | 3.5% | 7.0% | 12.8% | -8.1% | -14.2% | -30.5% | -103.1% | -267.1% |
| Pre-tax income | -48.1 | 16.2 | 30.5 | -16.8 | -26.4 | -24.5 | -30.5 | -30.5 |
| Income taxes | -26.2 | -20.8 | 0.9 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
| Tax rate | 54.5% | | 2.9% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% |
| Net income | -21.9 | 37.0 | 29.6 | -16.8 | -26.4 | -24.5 | -30.5 | -30.5 |
| Net margin | -6.9% | 12.8% | 12.1% | -9.2% | -17.3% | -33.1% | -104.5% | -253.7% |
| |
| Diluted EPS | ($0.67) | $1.13 | $0.99 | ($0.60) | ($1.31) | ($12.53) | ($17.13) | ($19.79) |
| Shares outstanding (diluted) | 32.4 | 32.7 | 29.9 | 28.0 | 20.1 | 2.0 | 1.8 | 1.5 |
| |
| EBIT is a non-GAAP figure that excludes all non-recurring expenses: restructuring costs, asset impairments, IPR&D writeoffs, and other unusual charges. |
|
|